Capecitabine, DNA/RNA Synthesis Inhibitor

Capecitabine is an oral proagent that is converted to its active metabolite, 5-FU, by thymidine phosphorylase. - Mechanism of Action & Protocol.

Capecitabine, C15H22FN3O6

Regulation of thymidylate synthase: an approach to overcome 5-FU resistance in colorectal cancer

is a tumor-selective fluoropyrimidine carbamate, which achieves higher intratumoral 5-FU level with lower toxicity than 5-FU.

Capecitabine

Mechanism of action of 5-fluorouracil: Capecitabine is a prodrug that

5‑Fluorouracil and capecitabine therapies for the treatment of colorectal cancer (Review)

Chemotherapeutic agents - Knowledge @ AMBOSS

POR Clinical benefits of oral capecitabine over intravenous 5-fluorouracyl regimen in case of neoadjuvant chemoradiotherapy followed by surgery for locally advanced rectal cancer

Anti-Cancer Drugs-Medicinal Chemistry

THOC5 complexes with DDX5, DDX17, and CDK12 to regulate R loop structures and transcription elongation rate

Effects of microbiota on anticancer drugs: Current knowledge and potential applications - eBioMedicine

Capecitabine

Capecitabine induces hand-foot syndrome through elevated thymidine phosphorylase-mediated locoregional toxicity and GSDME-driven pyroptosis that can be relieved by tipiracil

Capecitabine

Cellular responses to replication stress: Implications in cancer biology and therapy.